\n<\/p>\n
\n\n\nAdd topic to email alerts\n<\/span>\n<\/p>\n\n\n\nReceive an email when new articles are posted on \n<\/p>\n\nPlease provide your email address to receive an email when new articles are posted on .<\/p>\n<\/div>\n<\/div>\n” data-action=subscribe>\nSubscribe\n<\/button>\n<\/div>\n<\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\nIn this video, Monica Avila<\/b>,<\/b> MD, MPH,<\/b> discusses final OS results from the phase 3 ROSELLA trial assessing the addition of relacorilant to nab-paclitaxel for patients with platinum-resistant ovarian cancer.<\/p>\nIn the trial, presented at Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer, patients were randomly assigned to relacorilant (Lifyorli, Corcept Therapeutics) plus nab-paclitaxel (Abraxane, Bristol Myers Squibb) or nab-paclitaxel alone.<\/p>\nAccording to Avila, a gynecologic oncologist at Moffitt Cancer Center, the median OS with the relacorilant regimen was 16 months vs. 12 months with nab-paclitaxel monotherapy. At 18 months, 46% of patients in the combination arm remained alive vs. 27% in the monotherapy arm.<\/p>\nFor more information:<\/h2>\n Monica Avila, MD, MPH<\/b>, <\/b>can be reached at monica.avila@moffitt.org.<\/p>\n
\nReceive an email when new articles are posted on \n<\/p>\n\nPlease provide your email address to receive an email when new articles are posted on .<\/p>\n<\/div>\n<\/div>\n” data-action=subscribe>\nSubscribe\n<\/button>\n<\/div>\n<\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\nIn this video, Monica Avila<\/b>,<\/b> MD, MPH,<\/b> discusses final OS results from the phase 3 ROSELLA trial assessing the addition of relacorilant to nab-paclitaxel for patients with platinum-resistant ovarian cancer.<\/p>\nIn the trial, presented at Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer, patients were randomly assigned to relacorilant (Lifyorli, Corcept Therapeutics) plus nab-paclitaxel (Abraxane, Bristol Myers Squibb) or nab-paclitaxel alone.<\/p>\nAccording to Avila, a gynecologic oncologist at Moffitt Cancer Center, the median OS with the relacorilant regimen was 16 months vs. 12 months with nab-paclitaxel monotherapy. At 18 months, 46% of patients in the combination arm remained alive vs. 27% in the monotherapy arm.<\/p>\nFor more information:<\/h2>\n Monica Avila, MD, MPH<\/b>, <\/b>can be reached at monica.avila@moffitt.org.<\/p>\n
” data-action=subscribe>\nSubscribe\n<\/button>\n<\/div>\n<\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\nIn this video, Monica Avila<\/b>,<\/b> MD, MPH,<\/b> discusses final OS results from the phase 3 ROSELLA trial assessing the addition of relacorilant to nab-paclitaxel for patients with platinum-resistant ovarian cancer.<\/p>\nIn the trial, presented at Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer, patients were randomly assigned to relacorilant (Lifyorli, Corcept Therapeutics) plus nab-paclitaxel (Abraxane, Bristol Myers Squibb) or nab-paclitaxel alone.<\/p>\nAccording to Avila, a gynecologic oncologist at Moffitt Cancer Center, the median OS with the relacorilant regimen was 16 months vs. 12 months with nab-paclitaxel monotherapy. At 18 months, 46% of patients in the combination arm remained alive vs. 27% in the monotherapy arm.<\/p>\nFor more information:<\/h2>\n Monica Avila, MD, MPH<\/b>, <\/b>can be reached at monica.avila@moffitt.org.<\/p>\n
Back to Healio<\/button><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\nIn this video, Monica Avila<\/b>,<\/b> MD, MPH,<\/b> discusses final OS results from the phase 3 ROSELLA trial assessing the addition of relacorilant to nab-paclitaxel for patients with platinum-resistant ovarian cancer.<\/p>\nIn the trial, presented at Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer, patients were randomly assigned to relacorilant (Lifyorli, Corcept Therapeutics) plus nab-paclitaxel (Abraxane, Bristol Myers Squibb) or nab-paclitaxel alone.<\/p>\nAccording to Avila, a gynecologic oncologist at Moffitt Cancer Center, the median OS with the relacorilant regimen was 16 months vs. 12 months with nab-paclitaxel monotherapy. At 18 months, 46% of patients in the combination arm remained alive vs. 27% in the monotherapy arm.<\/p>\nFor more information:<\/h2>\n Monica Avila, MD, MPH<\/b>, <\/b>can be reached at monica.avila@moffitt.org.<\/p>\n
In this video, Monica Avila<\/b>,<\/b> MD, MPH,<\/b> discusses final OS results from the phase 3 ROSELLA trial assessing the addition of relacorilant to nab-paclitaxel for patients with platinum-resistant ovarian cancer.<\/p>\n
In the trial, presented at Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer, patients were randomly assigned to relacorilant (Lifyorli, Corcept Therapeutics) plus nab-paclitaxel (Abraxane, Bristol Myers Squibb) or nab-paclitaxel alone.<\/p>\n
According to Avila, a gynecologic oncologist at Moffitt Cancer Center, the median OS with the relacorilant regimen was 16 months vs. 12 months with nab-paclitaxel monotherapy. At 18 months, 46% of patients in the combination arm remained alive vs. 27% in the monotherapy arm.<\/p>\n
Monica Avila, MD, MPH<\/b>, <\/b>can be reached at monica.avila@moffitt.org.<\/p>\n
![\"hemonc](\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/hot.svg?la=en&h=24&w=141&hash=2F86D471C8514C0E334E329AA799E8B4\")
\n<\/div>\n<\/div>\n<\/div>\n